Journal Article
. 2010 Dec;363(23).
doi: 10.1056/NEJMoa0910320.

Adjuvant docetaxel for high-risk, node-negative breast cancer

Miguel Martín 1 Miguel A Seguí  Antonio Antón  Amparo Ruiz  Manuel Ramos  Encarna Adrover  Ignacio Aranda  Alvaro Rodríguez-Lescure  Regina Grosse  Lourdes Calvo  Agustí Barnadas  Dolores Isla  Purificación Martinez del Prado  Manuel Ruiz Borrego  Jerzy Zaluski  Angels Arcusa  Montserrat Muñoz  José M López Vega  José R Mel  Blanca Munarriz  Cristina Llorca  Carlos Jara  Emilio Alba  Jesús Florián  Junfang Li  José A López García-Asenjo  Amparo Sáez  María José Rios  Sergio Almenar  Gloria Peiró  Ana Lluch  GEICAM 9805 Investigators  
  • PMID: 21121833
  •     68 citations


Background: A regimen of docetaxel, doxorubicin, and cyclophosphamide (TAC) is superior to a regimen of fluorouracil, doxorubicin, and cyclophosphamide (FAC) when used as adjuvant therapy in women with node-positive breast cancer. The value of taxanes in the treatment of node-negative disease has not been determined.

Methods: We randomly assigned 1060 women with axillary-node-negative breast cancer and at least one high-risk factor for recurrence (according to the 1998 St. Gallen criteria) to treatment with TAC or FAC every 3 weeks for six cycles after surgery. The primary end point was disease-free survival after at least 5 years of follow-up. Secondary end points included overall survival and toxicity.

Results: At a median follow-up of 77 months, the proportion of patients alive and disease-free was higher among the 539 women in the TAC group (87.8%) than among the 521 women in the FAC group (81.8%), representing a 32% reduction in the risk of recurrence with TAC (hazard ratio, 0.68; 95% confidence interval [CI], 0.49 to 0.93; P=0.01 by the log-rank test). This benefit was consistent, regardless of hormone-receptor status, menopausal status, or number of high-risk factors. The difference in survival rates (TAC, 95.2%; FAC, 93.5%) was not significant (hazard ratio, 0.76; 95% CI, 0.45 to 1.26); however, the number of events was small (TAC, 26; FAC, 34). Rates of grade 3 or 4 adverse events were 28.2% with TAC and 17.0% with FAC (P<0.001). Toxicity associated with TAC was diminished when primary prophylaxis with granulocyte colony-stimulating factor was provided.

Conclusions: As compared with adjuvant FAC, adjuvant TAC improved the rate of disease-free survival among women with high-risk, node-negative breast cancer. (Funded by GEICAM and Sanofi-Aventis; number, NCT00121992.).

Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer.
Roisin M Connolly, Michelle A Rudek, +10 authors, Antonio C Wolff.
Breast Cancer Res Treat, 2011 Feb 26; 127(1). PMID: 21350820    Free PMC article.
Breast cancer medications and vision: effects of treatments for early-stage disease.
Alvin Eisner, Shiuh-Wen Luoh.
Curr Eye Res, 2011 Aug 09; 36(10). PMID: 21819259    Free PMC article.
Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial.
Davide Bedognetti, Mario Roberto Sertoli, +12 authors, Paolo Bruzzi.
J Natl Cancer Inst, 2011 Sep 17; 103(20). PMID: 21921285    Free PMC article.
Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients.
Ying-Yi Qin, Hui Li, +8 authors, Jia He.
PLoS One, 2011 Nov 10; 6(11). PMID: 22069477    Free PMC article.
Systematic Review.
AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.
Christoph Thomssen, Anton Scharl, Nadia Harbeck.
Breast Care (Basel), 2011 Dec 14; 6(4). PMID: 22164127    Free PMC article.
First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis.
Yiwei Jiang, Wenjin Yin, +6 authors, Jinsong Lu.
PLoS One, 2012 Mar 08; 7(3). PMID: 22396769    Free PMC article.
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.
Lynnette Fernández-Cuesta, Catherine Oakman, +14 authors, Magali Olivier.
Breast Cancer Res, 2012 May 04; 14(3). PMID: 22551440    Free PMC article.
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.
Bruno Coudert, Bernard Asselain, +18 authors, UNICANCER Breast Group.
Oncologist, 2012 May 23; 17(7). PMID: 22610153    Free PMC article.
Triple-negative breast cancer: are we making headway at least?
Monica Arnedos, Celine Bihan, Suzette Delaloge, Fabrice Andre.
Ther Adv Med Oncol, 2012 Jul 04; 4(4). PMID: 22754593    Free PMC article.
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.
Lawrence N Shulman, Constance T Cirrincione, +12 authors, Clifford Hudis.
J Clin Oncol, 2012 Jul 25; 30(33). PMID: 22826271    Free PMC article.
Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.
Malek B Hannouf, Bin Xie, Muriel Brackstone, Gregory S Zaric.
BMC Cancer, 2012 Oct 04; 12. PMID: 23031196    Free PMC article.
Functional polymorphisms in xenobiotic metabolizing enzymes and their impact on the therapy of breast cancer.
Rosane Vianna-Jorge, Juliana Simões Festa-Vasconcellos, Sheyla Maria Torres Goulart-Citrangulo, Marcelo Sobral Leite.
Front Genet, 2013 Jan 25; 3. PMID: 23346096    Free PMC article.
BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling.
M Sung, P Giannakakou.
Oncogene, 2013 Mar 26; 33(11). PMID: 23524581    Free PMC article.
Toxicity Analysis in the ADEBAR Trial: Sequential Anthracycline-Taxane Therapy Compared with FEC120 for the Adjuvant Treatment of High-Risk Breast Cancer.
Alexandra Schönherr, Viktoria Aivazova-Fuchs, +14 authors, Brigitte Rack.
Breast Care (Basel), 2013 Aug 02; 7(4). PMID: 23904831    Free PMC article.
Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection.
A Romero, A Prat, +9 authors, M Martín.
Clin Transl Oncol, 2013 Aug 03; 16(4). PMID: 23907291
Effectiveness and complications of anthracycline and taxane in the therapy of breast cancer: a meta-analysis.
Qing-jing Feng, Feng Zhang, Xiao-yun Huang, Zhi-xiang Wu.
Pathol Oncol Res, 2013 Aug 28; 20(1). PMID: 23980023
Benefit risk assessment and update on the use of docetaxel in the management of breast cancer.
Scheryll Alken, Catherine M Kelly.
Cancer Manag Res, 2013 Oct 22; 5. PMID: 24143122    Free PMC article.
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis.
Bella Pajares, Marina Pollán, +16 authors, Emilio Alba.
Breast Cancer Res, 2013 Nov 07; 15(6). PMID: 24192331    Free PMC article.
Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer.
J Menis, C Twelves.
Breast Cancer (Dove Med Press), 2011 Jan 01; 3. PMID: 24367180    Free PMC article.
Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review.
Isabella Sperduti, Patrizia Vici, +6 authors, Clara Natoli.
J Exp Clin Cancer Res, 2014 Jan 21; 32. PMID: 24438135    Free PMC article.
Systematic Review.
Collagen gel droplet-embedded culture-drug sensitivity test and Ki67 expression in estrogen receptor-positive and HER2-negative breast cancer.
Katsunori Tozuka, Jun Horiguchi, +7 authors, Izumi Takeyoshi.
Mol Clin Oncol, 2013 Jan 01; 1(1). PMID: 24649129    Free PMC article.
Present status of adjuvant chemotherapy for elderly breast cancer patients.
Sibylle Loibl, Mattea Reinisch.
Breast Care (Basel), 2012 Dec 01; 7(6). PMID: 24715824    Free PMC article.
Side effects of standard adjuvant and neoadjuvant chemotherapy regimens according to age groups in primary breast cancer.
Mattea Reinisch, Gunter von Minckwitz, +6 authors, Sibylle Loibl.
Breast Care (Basel), 2014 Apr 10; 8(1). PMID: 24715845    Free PMC article.
Relationship between chemotherapy and prognosis in different subtypes of node-negative breast cancer.
Xia Liu, Yong Guan, +5 authors, Yun Niu.
Tumour Biol, 2014 May 28; 35(9). PMID: 24863944
Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).
Lawrence N Shulman, Donald A Berry, +12 authors, Eric P Winer.
J Clin Oncol, 2014 Jun 18; 32(22). PMID: 24934787    Free PMC article.
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.
Nicole M Davis, Melissa Sokolosky, +23 authors, James A McCubrey.
Oncotarget, 2014 Jul 23; 5(13). PMID: 25051360    Free PMC article.
Highly Cited. Review.
Chemotherapy in early breast cancer: when, how and which one?
Marcus Schmidt.
Breast Care (Basel), 2014 Sep 02; 9(3). PMID: 25177256    Free PMC article.
Human epidermal growth factor receptor 2 and estrogen receptor status in respect to tumor characteristics in non-metastatic breast cancer.
Hanifeh Mirtavoos-Mahyari, Adnan Khosravi, Zahra Esfahani-Monfared.
Tanaffos, 2014 Sep 06; 13(1). PMID: 25191491    Free PMC article.
Update on adjuvant chemotherapy for early breast cancer.
Murtuza M Rampurwala, Gabrielle B Rocque, Mark E Burkard.
Breast Cancer (Auckl), 2014 Oct 23; 8. PMID: 25336961    Free PMC article.
Current treatment of early breast cancer: adjuvant and neoadjuvant therapy.
Elizabeth Miller, Hee Jin Lee, +3 authors, Bora Lim.
F1000Res, 2014 Nov 18; 3. PMID: 25400908    Free PMC article.
Effects of combination therapy of docetaxel with selenium on the human breast cancer cell lines MDA-MB-231 and MCF-7.
Sang O Park, Young Bum Yoo, +6 authors, Kyoung Sik Park.
Ann Surg Treat Res, 2015 Feb 19; 88(2). PMID: 25692115    Free PMC article.
Overexpression of HER2/neu as a Prognostic Value in Iranian Women With Early Stage Breast Cancer; A Single Institute Study.
Hanifeh Mirtavoos Mahyari, Adnan Khosravi, +2 authors, Negin Khosravi.
Iran Red Crescent Med J, 2015 Mar 13; 16(11). PMID: 25763209    Free PMC article.
An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy.
Wei Zhang, Zhiwei Jiang, +2 authors, Jielai Xia.
Med Oncol, 2015 Mar 31; 32(5). PMID: 25820754
Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.
S Gandhi, G G Fletcher, +4 authors, M E Trudeau.
Curr Oncol, 2015 Apr 08; 22(Suppl 1). PMID: 25848343    Free PMC article.
Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy-a survey of health care providers and patients.
Carmel Jacobs, Brian Hutton, +8 authors, Mark Clemons.
Support Care Cancer, 2015 May 03; 23(11). PMID: 25933700
Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort.
Meyha N Swaroop, Chantal M Ferguson, +8 authors, Alphonse G Taghian.
Breast Cancer Res Treat, 2015 May 06; 151(2). PMID: 25940996    Free PMC article.
Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
M Brito, S Esteves, +2 authors, A Moreira.
Support Care Cancer, 2015 Jun 27; 24(2). PMID: 26111956
Progress in adjuvant chemotherapy for breast cancer: an overview.
Jesus Anampa, Della Makower, Joseph A Sparano.
BMC Med, 2015 Aug 19; 13. PMID: 26278220    Free PMC article.
Highly Cited. Review.
Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
Takeo Fujii, Fanny Le Du, +6 authors, Naoto T Ueno.
JAMA Oncol, 2015 Sep 25; 1(9). PMID: 26402167    Free PMC article.
Systematic Review.
Attitudes and practice patterns for maintaining relative dose intensity of chemotherapy in outpatient clinics: results of a Japanese web-based survey.
Hitomi Sakai, Noriyuki Katsumata, Genmu Kadokura.
BMC Cancer, 2015 Oct 07; 15. PMID: 26438185    Free PMC article.
Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study.
S Rahal, J M Boher, +12 authors, A Gonçalves.
BMC Cancer, 2015 Oct 16; 15. PMID: 26466893    Free PMC article.
Biologic subtype is a more important prognostic factor than nodal involvement in patients with stages I and II breast carcinoma.
Hyosun Kim, Jihyoung Cho, Sun Young Kwon, Sun Hee Kang.
Ann Surg Treat Res, 2016 Jan 23; 90(1). PMID: 26793686    Free PMC article.
Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients.
Roberto Guariglia, Maria Carmen Martorelli, +3 authors, Pellegrino Musto.
Biologics, 2016 Feb 10; 10. PMID: 26858523    Free PMC article.
Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer.
Heather Greenlee, Katherine D Crew, +9 authors, Dawn L Hershman.
Breast Cancer Res Treat, 2016 Mar 26; 156(3). PMID: 27013473    Free PMC article.
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.
Z A Nahleh, W E Barlow, +11 authors, G N Hortobagyi.
Breast Cancer Res Treat, 2016 Jul 10; 158(3). PMID: 27393622    Free PMC article.
Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer.
Giuseppina Rosaria Rita Ricciardi, Tindara Franchina, +3 authors, Vincenzo Adamo.
Onco Targets Ther, 2016 Aug 09; 9. PMID: 27499629    Free PMC article.
ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.
Christopher Coyle, Fay H Cafferty, +11 authors, Add-Aspirin investigators.
Contemp Clin Trials, 2016 Oct 30; 51. PMID: 27777129    Free PMC article.
Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance.
Derek W Edwardson, Justin Boudreau, +3 authors, Amadeo M Parissenti.
PLoS One, 2017 Sep 16; 12(9). PMID: 28915246    Free PMC article.
Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience.
Marcus Vetter, Spyridon Fokas, +6 authors, Rosanna Zanetti-Dällenbach.
Oncotarget, 2017 Nov 02; 8(43). PMID: 29088896    Free PMC article.
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Eleftherios P Mamounas, Gong Tang, +14 authors, Norman Wolmark.
Breast Cancer Res Treat, 2017 Nov 13; 168(1). PMID: 29128898    Free PMC article.
Identifying accessible prognostic factors for breast cancer relapse: a case-study on 405 histologically confirmed node-negative patients.
Ines Zemni, Montassar Ghalleb, +5 authors, Khaled Rahal.
World J Surg Oncol, 2017 Nov 25; 15(1). PMID: 29169398    Free PMC article.
Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study.
Steffen Dörfel, Claus-Christoph Steffens, +6 authors, TMK-Group (Tumour Registry Breast Cancer).
Breast Cancer, 2017 Dec 06; 25(3). PMID: 29204847    Free PMC article.
The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Frédérique Penault-Llorca, Thomas Filleron, +12 authors, Henri Roché.
BMC Cancer, 2018 May 08; 18(1). PMID: 29728098    Free PMC article.
Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy.
Jihyoun Lee, Jong Eun Lee, +5 authors, Cheol Wan Lim.
Ann Surg Treat Res, 2018 May 08; 94(5). PMID: 29732352    Free PMC article.
Taxanes for adjuvant treatment of early breast cancer.
Melina L Willson, Lucinda Burke, +3 authors, Nicholas Wilcken.
Cochrane Database Syst Rev, 2019 Sep 03; 9. PMID: 31476253    Free PMC article.
Systematic Review.
Ezrin, more than a metastatic detERMinant?
Victoria Hoskin, Abdi Ghaffari, Bruce E Elliott.
Oncotarget, 2019 Dec 13; 10(63). PMID: 31827718    Free PMC article.
Influence of the Sense of Coherence, the Doctor-Patient Relationship, Optimism and Non-Haematological Adverse Reactions on Health-Related Quality of Life in Patients with Breast Cancer.
Blanca Prieto-Callejero, Francisco Rivera, Montserrat Andrés-Villas, Juan Gómez-Salgado.
J Clin Med, 2019 Nov 27; 8(12). PMID: 31766496    Free PMC article.
Early neutropenia on day 8 treated with adjuvant Docetaxel-based chemotherapy in early breast cancer patients: Putative mechanisms within the neutrophil pool system.
Yoshihiko Furuya.
PLoS One, 2019 Apr 19; 14(4). PMID: 30998754    Free PMC article.
The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy.
Erina Hilaj, Alketa Ymeri, Kleva P Shpati.
Cureus, 2020 Apr 08; 12(2). PMID: 32257663    Free PMC article.
EIF2A promotes cell survival during paclitaxel treatment in vitro and in vivo.
Lin Chen, Jiang He, +5 authors, Lun-Quan Sun.
J Cell Mol Med, 2019 Jun 19; 23(9). PMID: 31211507    Free PMC article.
Clinicopathological and Prognostic Characteristics of Malaysian Triple Negative Breast Cancer Patients Undergoing TAC Chemotherapy Regimen.
Ahmad Aizat Abdul Aziz, Md Salzihan Md Salleh, Ravindran Ankathil.
Int J Breast Cancer, 2020 Apr 21; 2020. PMID: 32308997    Free PMC article.
Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review.
Adam S Komorowski, Helen J MacKay, Rossanna C Pezo.
Cancer Med, 2020 May 27; 9(14). PMID: 32452660    Free PMC article.
Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer.
Blanca Prieto-Callejero, Francisco Rivera, +4 authors, Carlos Ruiz-Frutos.
Medicine (Baltimore), 2020 Sep 03; 99(33). PMID: 32872042    Free PMC article.
Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies.
Shani Paluch-Shimon, Nathan I Cherny, +4 authors, Fatima Cardoso.
ESMO Open, 2020 Sep 08; 5(5). PMID: 32893189    Free PMC article.
First line Immunotherapy for Non-Small Cell Lung Cancer.
Nicola J Nasser, Miguel Gorenberg, Abed Agbarya.
Pharmaceuticals (Basel), 2020 Nov 12; 13(11). PMID: 33171686    Free PMC article.
Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis.
Y Shen, T Fujii, +5 authors, L Xiao.
Breast Cancer Res Treat, 2018 Sep 23; 173(1). PMID: 30242579    Free PMC article.
Taxane-based chemotherapy and risk of breast cancer-related lymphedema: Protocol for a systematic review and meta-analysis.
Zhenhua Zhang, Xiwen Zhang, +7 authors, Baojin Hua.
Medicine (Baltimore), 2019 Jul 28; 98(30). PMID: 31348280    Free PMC article.
Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts.
Miguel Martin, Rocio Ramos-Medina, +20 authors, Sara Lopez-Tarruella.
Sci Rep, 2021 Mar 31; 11(1). PMID: 33782404    Free PMC article.